Cabaletta Bio

Cabaletta Bio is thrilled to welcome accomplished biotech veteran Steve Gavel as Chief Commercial Officer to lead the prelaunch planning and potential launch of rese-cel with the initial planned BLA filing in 2027! Steve brings extensive cell and gene therapy commercial leadership experience to Cabaletta, including commercial leadership at Legend for the launch and growth of CARVYKTI from 2018-2025. Read our press release here: https://lnkd.in/eGqYxG2J #CART #CellTherapy #RESET #Autoimmune #CabalettaCrew

Cabaletta Bio is thrilled to present the first rese-cel data with no preconditioning today at the European Society of Gene and Cell Therapy Annual Congress! In our late-breaking clinical oral presentation, we share that a single infusion of rese-cel without preconditioning can achieve complete B cell depletion and meaningful early clinical responses in patients with #pemphigusvulgaris. These data also highlight the broader opportunity for this simplified regimen to expand rese-cel access to patients who may desire a treatment option without preconditioning. Read our press release https://lnkd.in/esSub2KM #CART #celltherapy #reset #autoimmune #ESGCT

Cabaletta Bio is thrilled to share that our company has been nationally recognized by Fortune for the third year in a row as one of the Top 10 Best Small / Medium Biotech Companies list and as a Great Place To Work ! This recognition is a testament to the incredible culture we've built together - one rooted in purpose, innovation, and care. In the fast-moving world of cell therapy, it’s our people who make the difference.    To our team: thank you for making this such a special place to work every day and year. Your commitment to patients, science, and each other is what sets us apart. Let’s keep building something extraordinary - together. #GreatPlaceToWork #CellTherapy #TeamCulture #HRLeadership #BiotechTop10 #EmployeeExperience #PurposeDrivenWork https://lnkd.in/geDbFfdx

Our CEO, Steven Nichtberger, MD, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 today, September 3rd. Join the live webcast at 10:55am ET at the following link: https://lnkd.in/e4BQCa-z

Today Cabaletta Bio reported its second quarter 2025 financial results and provided a business update. We highlighted advancements across our RESET™ clinical development program for rese-cel along with our progress toward regulatory interactions to enable additional registrational pathways for rese-cel in autoimmune diseases. Read our full press release here: https://lnkd.in/eS2uzYtC #celltherapy #reset #autoimmune

Cabaletta Bio is encouraged to see The New York Times spotlighting the potential of CAR-T cell therapy in advancing lupus treatment. At Cabaletta, we are deeply committed to developing rese-cel for patients, and it is inspiring to take part in the mission to offer new hope for people living with lupus.   If you or a loved one is affected by lupus, we encourage you to stay informed and consult with your healthcare provider about emerging therapies. For more resources and updates, visit our website or connect with our community.   https://lnkd.in/e3_A3aFu   #LupusAwareness #CAR-T #PatientAdvocacy

Cabaletta Bio is honored to have presented our latest rese-cel clinical and translational data in three separate oral sessions on the RESET-SLE, RESET-Myositis and RESET-SSc trials at the EULAR 2025 Congress last week. Our oral presentations are now available here: https://lnkd.in/eyWQjT68 #celltherapy #EULAR2025 #reset #autoimmune

Cabaletta Bio is honored to have all three oral presentations on rese-cel (RESET-Myositis, RESET-SSc and RESET-SLE) featured by EULAR - European Alliance of Associations for Rheumatology in its new press release, highlighting the potential of CAR T therapies to reset the immune system, allowing patients to achieve meaningful clinical responses without immunosuppressive therapies. #EULAR2025 #celltherapy #reset https://lnkd.in/eThpcJ-e

This morning, Cabaletta Bio announced new safety and efficacy data from 18 patients in the ongoing RESET-Myositis, RESET-SLE and RESET-SSc trials. These findings reinforce our belief that a single, weight-based dose of rese-cel can lead to deep B cell depletion and compelling clinical data in patients with myositis, lupus and systemic sclerosis, without the need for immunomodulators and steroids. Learn more here: https://lnkd.in/epB6m7z4 #celltherapy #EULAR2025 #reset #autoimmune

Our CEO, Steven Nichtberger, will participate in a fireside chat at the Jefferies Global Healthcare Conference today, June 4th. Join the live webcast at 11:05am ET at the following link: https://lnkd.in/eft2ragF #jefferies #celltherapy #reset #autoimmune